Discovery and Clinical Evaluation of MK-8150, A Novel Nitric Oxide Donor With a Unique Mechanism of Nitric Oxide Release
Clayton D Knox, Pieter-Jan de Kam, Karim Azer, Peggy Wong, Antwan G Ederveen, Diane Shevell, Christopher Morabito, Alan G Meehan, Wen Liu, Tom Reynders, Jean Francois Denef, Anna Mitselos, Daniel Jonathan, David E Gutstein, Kaushik Mitra, Shu Yu Sun, Michael Man-Chu Lo, Doris Cully, Amjad Ali, Clayton D Knox, Pieter-Jan de Kam, Karim Azer, Peggy Wong, Antwan G Ederveen, Diane Shevell, Christopher Morabito, Alan G Meehan, Wen Liu, Tom Reynders, Jean Francois Denef, Anna Mitselos, Daniel Jonathan, David E Gutstein, Kaushik Mitra, Shu Yu Sun, Michael Man-Chu Lo, Doris Cully, Amjad Ali
Abstract
Background: Nitric oxide donors are widely used to treat cardiovascular disease, but their major limitation is the development of tolerance, a multifactorial process to which the in vivo release of nitric oxide is thought to contribute. Here we describe the preclinical and clinical results of a translational drug development effort to create a next-generation nitric oxide donor with improved pharmacokinetic properties and a unique mechanism of nitric oxide release through CYP3A4 metabolism that was designed to circumvent the development of tolerance.
Methods and results: Single- and multiple-dose studies in telemetered dogs showed that MK-8150 induced robust blood-pressure lowering that was sustained over 14 days. The molecule was safe and well tolerated in humans, and single doses reduced systolic blood pressure by 5 to 20 mm Hg in hypertensive patients. Multiple-dose studies in hypertensive patients showed that the blood-pressure-lowering effect diminished after 10 days, and 28-day studies showed that the hemodynamic effects were completely lost by day 28, even when the dose of MK-8150 was increased during the dosing period.
Conclusions: The novel nitric oxide donor MK-8150 induced significant blood-pressure lowering in dogs and humans for up to 14 days. However, despite a unique mechanism of nitric oxide release mediated by CYP3A4 metabolism, tolerance developed over 28 days, suggesting that tolerance to nitric oxide donors is multifactorial and cannot be overcome solely through altered in vivo release of nitric oxide.
Clinical trial registration: URL: http://www.clinicaltrials.gov. Unique identifiers: NCT01590810 and NCT01656408.
Keywords: blood pressure; nitrate; nitrate tolerance; nitric oxide; vasodilation.
© 2016 The Authors and Merck & Co., Inc. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.
Figures
References
- Waltz P, Escobar D, Zuckerbraun BS. Nitrate/nitrite as critical mediatiators to limit oxidative injury and inflammation. Antioxid Redox Signal. 2015;23:328–329.
- Thomas DD, Heinecke JL, Ridnour LA, Cheng RY, Kesarwala AH, Switzer CH, McVicar DW, Roberts DD, Glynn S, Fukuto JM, Wink DA, Miranda KM. Signaling and stress: the redox landscape in NOS2 biology. Free Radic Biol Med. 2015;87:204–225.
- Chirkov YY, Naujalis JI, Barber S, Sage RE, Gove DW, Brealey JK, Horowitz JD. Reversal of human platelet aggregation by low concentrations of nitroglycerin in vitro in normal subjects. Am J Cardiol. 1992;70:802–806.
- Sogo N, Magid KS, Shaw CA, Webb DJ, Megson IL. Inhibition of human platelet aggregation by nitric oxide donor drugs: relative contribution of cGMP‐independent mechanisms. Biochem Biophys Res Commun. 2000;279:412–419.
- Packer M, Lee WH, Kessler PD, Gottlieb SS, Medina N, Yushak M. Prevention and reversal of nitrate tolerance in patients with congestive heart failure. N Engl J Med. 1987;317:799–804.
- Parker JD, Farrell B, Fenton T, Cohanim M, Parker JO. Counter‐regulatory responses to continuous and intermittent therapy with nitroglycerin. Circulation. 1991;84:2336–2345.
- Azevedo ER, Schofield AM, Kelly S, Parker JD. Nitroglycerin withdrawal increases endothelium‐dependent vasomotor response to acetylcholine. J Am Coll Cardiol. 2001;37:505–509.
- Munzel T, Daiber A, Gori T. More answers to the still unresolved question of nitrate tolerance. Eur Heart J. 2013;34:2666–2673.
- Munzel T, Daiber A, Gori T. Nitrate therapy: new aspects concerning molecular action and tolerance. Circulation. 2011;123:2132–2144.
- Keefer LK. Fifty years of diazeniumdiolate research. From laboratory curiosity to broad spectrum biochemical advances. ACS Chem Biol. 2011;6:1147–1155.
- Ali A, Lo MM, Whitehead B, Shah SK, Henderson TJ, Lin Y, Guo Z. Preparation of diazeniumdiolate heterocyclic derivatives as antihypertensive agents. WO Patent 2012122077, September 13, 2012.
- Lin JH, Chen I‐W, Ciba M, Nishime JA, Deluna F. Route‐dependent nonlinear pharmacokineticsof a novel HIV protease inhibitor: involvement of enzyme inactivation. Drug Metab Dispos. 2000;28:460–466.
- Bagdy G, Riba P, Kecskeméti V, Chase D, Juhász G. Headache‐type adverse effects of NO donors: vasodilation and beyond. Br J Pharmacol. 2010;160:20–35.
- Munzel T, Heitzer T, Kurz S, Harrison DG, Luhman C, Pape L, Olschewski M, Just H. Dissociation of coronary vascular tolerance and neurohormonal adjustments during long‐term nitroglycerin therapy in patients with stable coronary artery disease. J Am Coll Cardiol. 1996;27:297–303.
- Schulz E, Tsilimingas N, Rinze R, Reiter B, Wendt M, Oelze M, Woelken‐Weckmuller S, Walter U, Reichenspurner H, Meinertz T, Munzel T. Functional and biochemical analysis of endothelial (dys) function and NO/cGMP signaling in human blood vessels with and without nitroglycerin pretreatment. Circulation. 2002;105:1170–1175.
Source: PubMed